STOCK TITAN

Catherine T. Doherty sells 26,165 Quest Diagnostics shares (DGX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Quest Diagnostics reported an insider sale and recent restricted stock vesting. Catherine T. Doherty sold 26,165 Common shares on 02/13/2026 for $5,393,815.32. The filing also lists restricted stock vesting of 726 shares on 02/12/2026 and 707 shares on 02/14/2026, each labeled as Issuer compensation.

Positive

  • None.

Negative

  • None.

Insights

Disclosure shows a single notable sale plus small vesting events by an insider.

The filing records a sale of 26,165 Common shares on 02/13/2026 for $5,393,815.32, and two restricted stock vesting events of 726 and 707 shares on 02/12/2026 and 02/14/2026, respectively.

These items are routine insider disclosures under Rule 144; the sale's materiality relative to total outstanding shares is not provided in the excerpt, so actual portfolio impact depends on ownership context and is not determinable here.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the DGX Form 144 disclose about insider sales?

The Form 144 reports that Catherine T. Doherty sold 26,165 Common shares on 02/13/2026 for $5,393,815.32. This is the primary sale disclosed in the provided excerpt.

Did the DGX filing report any restricted stock vesting?

Yes. The excerpt lists restricted stock vesting of 726 shares on 02/12/2026 and 707 shares on 02/14/2026, both described as Issuer compensation events.

Who is the insider named in the DGX filing?

The filing names Catherine T. Doherty with an address on the disclosure and records her sale of 26,165 Common shares on 02/13/2026 for $5,393,815.32.

Does the Form 144 state the proceeds recipient for the DGX sale?

The excerpt shows a sale amount of $5,393,815.32 tied to the 26,165 shares sold on 02/13/2026; the filing format implies proceeds relate to the reporting person’s transaction.

Are the vesting events in the DGX excerpt listed as compensation?

Yes. The restricted stock vesting entries of 726 and 707 shares are labeled in the excerpt as Restricted Stock Vesting and identified as Issuer compensation.
Quest Diagnostics Inc

NYSE:DGX

DGX Rankings

DGX Latest News

DGX Latest SEC Filings

DGX Stock Data

22.53B
109.50M
Diagnostics & Research
Services-medical Laboratories
Link
United States
SECAUCUS